Interview with the CEO: Dynavax Technologies Corporation (DVAX)
Eddie Gray joined Dynavax Technologies Corporation as Chief Executive Officer and was appointed to the board in May 2013. Most recently, Mr. Gray served as the President of Pharmaceuticals Europe at GlaxoSmithKline plc (GSK) since 2008, and as Senior Vice President and General Manager of Pharmaceuticals UK from 2001 through 2007. Prior to the formation of GSK, Mr. Gray was with SmithKline Beecham from 1988 through 2000 serving in various positions of increasing responsibility, including Vice President and Director of Anti-Infectives Marketing in the U.S., Vice President and Director of the Vaccines Business Unit in the U.S., and Vice President and General Manager of Pharmaceuticals in Canada. Mr. Gray received a Bachelor of Science degree in chemistry and management studies from the University of London, and an MBA from the Cranfield School of Management in the U.K. Profile
TWST: I’d like to start by asking you to give us a brief overview of Dynavax’s business.
Mr. Gray: Dynavax is a publicly traded, biopharmaceutical company, and our focus is